JPH072631B2 - Gel composition - Google Patents
Gel compositionInfo
- Publication number
- JPH072631B2 JPH072631B2 JP62050354A JP5035487A JPH072631B2 JP H072631 B2 JPH072631 B2 JP H072631B2 JP 62050354 A JP62050354 A JP 62050354A JP 5035487 A JP5035487 A JP 5035487A JP H072631 B2 JPH072631 B2 JP H072631B2
- Authority
- JP
- Japan
- Prior art keywords
- oil
- gel composition
- fat
- solid
- fatty acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000203 mixture Substances 0.000 title claims description 40
- 239000007787 solid Substances 0.000 claims description 16
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 15
- 239000000194 fatty acid Substances 0.000 claims description 15
- 229930195729 fatty acid Natural products 0.000 claims description 15
- -1 fatty acid ester Chemical class 0.000 claims description 15
- 229920001296 polysiloxane Polymers 0.000 claims description 14
- 125000004122 cyclic group Chemical group 0.000 claims description 12
- 239000003349 gelling agent Substances 0.000 claims description 10
- 150000003904 phospholipids Chemical class 0.000 claims description 10
- 239000004375 Dextrin Substances 0.000 claims description 7
- 229920001353 Dextrin Polymers 0.000 claims description 7
- 229930006000 Sucrose Natural products 0.000 claims description 7
- 235000019425 dextrin Nutrition 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- 239000005720 sucrose Substances 0.000 claims description 7
- 239000001913 cellulose Chemical class 0.000 claims description 5
- 229920002678 cellulose Chemical class 0.000 claims description 5
- 239000003883 ointment base Substances 0.000 claims description 5
- HMMGMWAXVFQUOA-UHFFFAOYSA-N octamethylcyclotetrasiloxane Chemical group C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 HMMGMWAXVFQUOA-UHFFFAOYSA-N 0.000 claims description 4
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 claims description 3
- 239000003921 oil Substances 0.000 description 21
- 235000019198 oils Nutrition 0.000 description 21
- 239000003925 fat Substances 0.000 description 17
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 239000004264 Petrolatum Substances 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
- 239000012188 paraffin wax Substances 0.000 description 4
- 229940066842 petrolatum Drugs 0.000 description 4
- 235000019271 petrolatum Nutrition 0.000 description 4
- 239000004166 Lanolin Substances 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 235000019388 lanolin Nutrition 0.000 description 3
- 229940039717 lanolin Drugs 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 229940099259 vaseline Drugs 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 2
- LFYJSSARVMHQJB-QIXNEVBVSA-N bakuchiol Chemical compound CC(C)=CCC[C@@](C)(C=C)\C=C\C1=CC=C(O)C=C1 LFYJSSARVMHQJB-QIXNEVBVSA-N 0.000 description 2
- 235000013871 bee wax Nutrition 0.000 description 2
- 239000012166 beeswax Substances 0.000 description 2
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 2
- FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
- 235000014593 oils and fats Nutrition 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- BGRXBNZMPMGLQI-UHFFFAOYSA-N 2-octyldodecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCC(CCCCCCCC)CCCCCCCCCC BGRXBNZMPMGLQI-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 229920000896 Ethulose Polymers 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- 239000001859 Ethyl hydroxyethyl cellulose Substances 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical class OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 108010093965 Polymyxin B Proteins 0.000 description 1
- 229920000153 Povidone-iodine Polymers 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000411545 Punargentus Species 0.000 description 1
- 241001237745 Salamis Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960005274 benzocaine Drugs 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 239000010495 camellia oil Substances 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 229940046978 chlorpheniramine maleate Drugs 0.000 description 1
- 150000001841 cholesterols Chemical class 0.000 description 1
- 229960001747 cinchocaine Drugs 0.000 description 1
- PUFQVTATUTYEAL-UHFFFAOYSA-N cinchocaine Chemical compound C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 description 1
- 150000001851 cinnamic acid derivatives Chemical class 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 229960000525 diphenhydramine hydrochloride Drugs 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 235000019326 ethyl hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- SFFVATKALSIZGN-UHFFFAOYSA-N hexadecan-7-ol Chemical compound CCCCCCCCCC(O)CCCCCC SFFVATKALSIZGN-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 229940073665 octyldodecyl myristate Drugs 0.000 description 1
- 229940060184 oil ingredients Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000003504 photosensitizing agent Substances 0.000 description 1
- 229920000024 polymyxin B Polymers 0.000 description 1
- 229960005266 polymyxin b Drugs 0.000 description 1
- 229960001621 povidone-iodine Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 235000015175 salami Nutrition 0.000 description 1
- 229940058287 salicylic acid derivative anticestodals Drugs 0.000 description 1
- 150000003872 salicylic acid derivatives Chemical class 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 229960004880 tolnaftate Drugs 0.000 description 1
- FUSNMLFNXJSCDI-UHFFFAOYSA-N tolnaftate Chemical compound C=1C=C2C=CC=CC2=CC=1OC(=S)N(C)C1=CC=CC(C)=C1 FUSNMLFNXJSCDI-UHFFFAOYSA-N 0.000 description 1
- LOIYMIARKYCTBW-OWOJBTEDSA-N trans-urocanic acid Chemical compound OC(=O)\C=C\C1=CNC=N1 LOIYMIARKYCTBW-OWOJBTEDSA-N 0.000 description 1
- LOIYMIARKYCTBW-UHFFFAOYSA-N trans-urocanic acid Natural products OC(=O)C=CC1=CNC=N1 LOIYMIARKYCTBW-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 229960001296 zinc oxide Drugs 0.000 description 1
- 229930007845 β-thujaplicin Natural products 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/042—Gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
- A61K8/553—Phospholipids, e.g. lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/58—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing atoms other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur or phosphorus
- A61K8/585—Organosilicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/731—Cellulose; Quaternized cellulose derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/732—Starch; Amylose; Amylopectin; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Dispersion Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
Description
【発明の詳細な説明】 ［産業上の利用分野］ 本発明はゲル状組成物に関する。本発明のゲル状組成物
は皮膚科用および化粧用の軟膏剤に使用される。TECHNICAL FIELD The present invention relates to a gel composition. The gel composition of the present invention is used for dermatological and cosmetic ointments.
［従来の技術］ 軟膏基剤として従来、オクタメチルシクロテトラシロキ
サン等の低分子環状シリコーンとワセリンとの混合物が
知られている（特開昭56-145212号）。この軟膏基剤に
おいては、べとつきや高い粘度のため厚く塗られてしま
うというワセリンの欠点は改善されているが、ワセリン
の環状シリコーンへの溶解は必ずしも充分ではなく、高
温時には溶解しても冷却したとき、その一部が結晶とし
て析出し、ボソボソした使用感を与え、また時間の経過
とともにこの結晶粒が増大し、使用感が悪化する欠点を
有していた。[Prior Art] As an ointment base, a mixture of low molecular cyclic silicone such as octamethylcyclotetrasiloxane and petrolatum has been conventionally known (JP-A-56-145212). In this ointment base, the disadvantage of petrolatum that it is thickly applied due to stickiness and high viscosity has been improved, but the solubility of petrolatum in cyclic silicone is not always sufficient, and even if dissolved at high temperature, it was cooled. At this time, a part of them is deposited as crystals, which gives a rough feeling of use, and the number of crystal grains increases with the lapse of time, resulting in a bad feeling of use.
［発明が解決しようとする問題点］ 本発明の目的は、上述したワセリン（油脂分）の晶出や
結晶の増大を防止した、べとつきのない優れた使用感を
有するゲル状組成物を提供することにある。[Problems to be Solved by the Invention] An object of the present invention is to provide a gel composition having an excellent usability without stickiness, which prevents the above-mentioned crystallization of vaseline (oil and fat) and the increase of crystals. Especially.
［問題点を解決するための手段］ 本発明の上記目的は、下記の構成を有する本発明のゲル
状組成物によって達成される。[Means for Solving Problems] The above object of the present invention is achieved by the gel composition of the present invention having the following constitution.
１）半固型油脂分10〜90％（組成物全量中の重量パーセ
ント、以下同じ）と、低分子環状シリコーン90〜10％と
ゲル化剤１〜10％とを含有してなり、前記半固型油脂分
は常温で固型である油脂５〜45％と、常温で液状である
油脂５〜45％とからなる、ゲル状組成物。1) Semi-solid fat and oil content of 10 to 90% (weight percentage in the total amount of the composition, the same applies below), low molecular cyclic silicone 90 to 10% and gelling agent 1 to 10%, A gel composition comprising 5 to 45% of fats and oils that are solid at room temperature and 5 to 45% of fats and oils that are liquid at room temperature.
２）環状シリコーンがオクタメチルシクロテトラシロキ
サンもしくはデカメチルシクロペンタシロキサンまたは
それらの混合物である前記第１項記載のゲル状組成物。2) The gel composition according to the above item 1, wherein the cyclic silicone is octamethylcyclotetrasiloxane, decamethylcyclopentasiloxane, or a mixture thereof.
３）ゲル化剤がデキストリン脂肪酸エステル、ショ糖脂
肪酸エステル、セルロース誘導体およびリン脂質の１種
または２種以上よりなる前記第１項記載のゲル状組成
物。3) The gel composition according to the above item 1, wherein the gelling agent is one or more of dextrin fatty acid ester, sucrose fatty acid ester, cellulose derivative and phospholipid.
４）ゲル状組成物がゲル軟膏基剤である前記第１項記載
のゲル状組成物。4) The gel composition according to the above item 1, wherein the gel composition is a gel ointment base.
本発明は上述したように、半固型油脂分と低分子環状シ
リコーンとゲル化剤を含有したゲル状組成物である。As described above, the present invention is a gel composition containing a semi-solid oil / fat, a low molecular weight cyclic silicone and a gelling agent.
本発明で使用される半固型油脂分には特に制限はない
が、常温で固型であるものと、液状であるものとの混合
物が望ましい。常温で固型の油脂分の例としては、ワセ
リン、ラノリン、ラノリン誘導体、プラスチベース（商
品名）、ワックス類（例えばマイクロクリスタリンワッ
クス、ビーズワックス）、固型パラフィン、硬化油、高
級アルコール（例えばセタノール、ステアリルアルコー
ル）、コレステロール、コレステロール誘導体等があげ
られる。常温で液体の油脂分の例としては、流動パラフ
ィン、高級脂肪酸エステル（例えば、ミリスチン酸イソ
プロピル、ミリスチン酸オクチルドデシル、パルミチン
酸イソプロピル等）、高級アルコール（例えばオクタノ
ール、ヘキシルデカノール、オクチルドデカノール
等）、植物油（例えばツバキ油、オリーブ油、ヒマシ油
等）、スクアラン等があげられる。油脂分はゲル状組成
物全量の10〜90％（重量パーセント、以下同じ）であ
り、固型油脂５〜45％、液状油脂５〜45％が望ましい。The semi-solid fats and oils used in the present invention are not particularly limited, but a mixture of one that is solid at room temperature and one that is liquid is desirable. Examples of oils and fats that are solid at room temperature include petrolatum, lanolin, lanolin derivatives, plastibase (trade name), waxes (for example, microcrystalline wax, beeswax), solid paraffin, hydrogenated oil, higher alcohols (for example, cetanol, Stearyl alcohol), cholesterol, cholesterol derivatives and the like. Examples of oils and fats that are liquid at room temperature include liquid paraffin, higher fatty acid esters (eg, isopropyl myristate, octyldodecyl myristate, isopropyl palmitate, etc.), higher alcohols (eg, octanol, hexyldecanol, octyldodecanol, etc.), vegetable oils. (For example, camellia oil, olive oil, castor oil, etc.) and squalane. The oil and fat content is 10 to 90% (weight percent, the same applies hereinafter) of the total amount of the gel composition, and solid oil and fat 5 to 45% and liquid oil and fat 5 to 45% are desirable.
本発明に用いられる低分子環状シリコーンとしては、オ
クタメチルシクロテトラシロキサンもしくはデカメチル
シクロペンタシロキサンまたはそれらの混合物（例えば
東レシリコーン社製、SH-344,DC-345）が好ましく、そ
の配合量は全基剤量の90〜10％、好ましくは50〜20％で
ある。As the low molecular weight cyclic silicone used in the present invention, octamethylcyclotetrasiloxane or decamethylcyclopentasiloxane or a mixture thereof (for example, Toray Silicone Co., Ltd., SH-344, DC-345) is preferable, and the total amount thereof is It is 90 to 10% of the base amount, preferably 50 to 20%.
ゲル化剤としてはデキストリン脂肪酸エステル、ショ糖
脂肪酸エステル、セルロース誘導体、リン脂質等が用い
られる。デキストリン脂肪酸エステルはデキストリンの
水酸基に炭素数12〜18の脂肪酸がエステル結合したもの
で、水酸基のほとんどがエステル化されているものが用
いられる。例えばレオパールKE,KL（千葉製粉社製）が
好適である。ショ糖脂肪酸エステルは、ショ糖の水酸基
が炭素数４〜22個の脂肪酸によりエステル化されたもの
で、HLBが１〜２のもの（例えばDK−エステルF10,F20,
第一化学薬品社製）、または残余の水酸基がアセチル化
されたもの（例えばDK−エステルFA−10E,第一化学薬品
社製）が用いられる。セルロース誘導体はエチルセルロ
ース、エチルヒドロキシエチルセルロース等油溶性のも
のが好適に使用される。As the gelling agent, dextrin fatty acid ester, sucrose fatty acid ester, cellulose derivative, phospholipid and the like are used. As the dextrin fatty acid ester, a fatty acid having 12 to 18 carbon atoms is ester-bonded to the hydroxyl group of dextrin, and most of the hydroxyl groups are esterified. For example, Leopard KE, KL (manufactured by Chiba Flour Milling Co.) is suitable. The sucrose fatty acid ester is one in which the hydroxyl group of sucrose is esterified with a fatty acid having 4 to 22 carbon atoms and has an HLB of 1 to 2 (for example, DK-ester F10, F20,
(Manufactured by Daiichi Pure Chemicals Co., Ltd.) or those in which residual hydroxyl groups are acetylated (for example, DK-ester FA-10E, manufactured by Daiichi Pure Chemicals Co., Ltd.) are used. As the cellulose derivative, oil-soluble ones such as ethyl cellulose and ethyl hydroxyethyl cellulose are preferably used.
リン脂質としては大豆レシチン、卵黄レシチンおよびそ
れらの水素添加したものを用いることができる。単一の
リン脂質のみから構成される必要はなく２種以上のリン
脂質を含んでいてもよくまたリン脂質以外の成分（例え
ば大豆油、卵黄油）を含んでいてもよいが、その使用量
はそれに含まれるリン脂質量に基づいて決定される。As the phospholipid, soybean lecithin, egg yolk lecithin and hydrogenated products thereof can be used. It does not have to be composed of only a single phospholipid and may contain two or more kinds of phospholipids, and may also contain components other than phospholipids (eg soybean oil, egg yolk oil), but the amount used Is determined based on the amount of phospholipids contained therein.
ゲル化剤の使用量は概ね全組成物量の１〜10％であるが
その種類によっても多少異なる。例えばデキストリン脂
肪酸エステルの場合は２〜10％、ショ糖脂肪酸エステル
は１〜10％、セルロース誘導体およびリン脂質は１〜３
％である。これらのゲル化剤は単独でも、また２種以上
を組み合せても使用することができる。The amount of the gelling agent used is generally 1 to 10% of the total amount of the composition, but it varies somewhat depending on the type. For example, 2 to 10% for dextrin fatty acid ester, 1 to 10% for sucrose fatty acid ester, 1 to 3 for cellulose derivative and phospholipid.
%. These gelling agents can be used alone or in combination of two or more kinds.
本発明のゲル状組成物は、固型油脂分、液状油脂分およ
びゲル化剤の混合物を高温（好ましくは75℃以上）で撹
拌し、均一な液体とし、これに同じく加熱した低分子環
状シリコーンを加え、よくかきまぜ均一に分散させた
後、かきまぜながら室温まで冷却することによって容易
に製造される。The gel composition of the present invention is a low-molecular cyclic silicone which is obtained by stirring a mixture of a solid fat and oil, a liquid fat and oil and a gelling agent at a high temperature (preferably 75 ° C. or higher) to obtain a uniform liquid, which is also heated. Is added, and the mixture is well stirred and uniformly dispersed, and then it is easily manufactured by cooling to room temperature while stirring.
本発明のゲル状組成物における油脂分対低分子環状シリ
コーンの使用量比は、25〜75％対75％〜25％、好ましく
は40〜70％対60〜30％、さらに好ましくは55〜65対45〜
35％である。The amount ratio of the oil / fat content to the low molecular weight cyclic silicone in the gel composition of the present invention is 25 to 75% to 75% to 25%, preferably 40 to 70% to 60 to 30%, and more preferably 55 to 65. Pair 45 ~
35%.
また本発明のゲル状組成物には、外用薬として使用され
ている種々の薬効成分を配合させることができる。Further, the gel composition of the present invention may be mixed with various medicinal components used as external medicines.
薬効成分の例としては次のものがあげられる。The following are examples of medicinal components.
（１）消炎剤 ハイドロコルチゾン、プレドニゾロン等のコルチコステ
ロイド、グリチルリチン酸、及びその塩、グリチルレチ
ン酸及びその誘導体、サリチル酸誘導体、アズレン等、
インドメタシン、イブプロフェン等非ステロイド抗炎症
剤。(1) Anti-inflammatory agent Corticosteroids such as hydrocortisone and prednisolone, glycyrrhizinic acid and salts thereof, glycyrrhetinic acid and its derivatives, salicylic acid derivatives, azulene, etc.
Non-steroidal anti-inflammatory drug such as indomethacin and ibuprofen.
（２）消毒・殺菌剤 塩化ベンザルコニウム、塩化ベンゼトニウム、クロルヘ
キシジルグルコネート、ポビドンヨード、ヒノキチオー
ル、感光素、（にきび用として）ベンゾイルパーオキシ
ド、硫黄、など（水虫用として）クロトリマゾール、ト
ルナフテートなど。(2) Disinfectants / Fungicides Benzalkonium chloride, benzethonium chloride, chlorhexidyl gluconate, povidone iodine, hinokitiol, photosensitizer, benzoyl peroxide (for acne), sulfur, etc. (for athlete's foot) clotrimazole, tolnaftate Such.
（３）ビタミン類・ホルモン ビタミンＡ、ビタミンＥ、アスコルビン及びその酸誘導
体、ビタミンB2,B6、ニコチン酸誘導体、パントテン酸
及びその誘導体、エストラジオール、など。(3) Vitamin / hormone Vitamin A, vitamin E, ascorbine and its acid derivative, vitamins B 2 and B 6 , nicotinic acid derivative, pantothenic acid and its derivative, estradiol, etc.
（４）抗ヒスタミン薬 塩酸ジフェンヒドラミン、マレイン酸クロルフェニラミ
ンなど。(4) Antihistamines Diphenhydramine hydrochloride, chlorpheniramine maleate, etc.
（５）日焼け止め ケイ皮酸エステル類、安息香酸誘導体、ウロカニン酸、
酸化チタンなど。(5) Sunscreen cinnamic acid esters, benzoic acid derivatives, urocanic acid,
Titanium oxide etc.
（６）局部麻酔剤類 ベンゾカイン、リドカイン、ジブカインなど。(6) Local anesthetics Benzocaine, lidocaine, dibucaine, etc.
（７）抗生物質 テトラサイクリン、ポリミキシンＢ、ゲンタマイシンな
ど。(7) Antibiotics Tetracycline, polymyxin B, gentamicin, etc.
（８）防腐剤 パラオキシ安息香酸誘導体など。(8) Preservatives Paraoxybenzoic acid derivatives and the like.
（９）その他・香草類抽出物、アラントイン及びその誘
導体、香油、メントール、カンフル、酸化亜鉛。(9) Others: Herb extracts, allantoin and its derivatives, perfume oil, menthol, camphor, zinc oxide.
次に実施例を示して本発明をさらに具体的に説明する。Next, the present invention will be described more specifically by showing examples.
実施例１ 上記本発明および比較例の各成分をそれぞれ透明溶液と
なるまで加温し、その後冷却した。Example 1 Each component of the present invention and the comparative example was heated until a transparent solution was formed, and then cooled.
注１）千葉製粉社製 デキストリン脂肪酸エステル 注２）第一化学薬品社製 ショ糖脂肪酸エステル 注３）東レシリコーン社製 低分子環状シリコーン混合物 実施例２ 本発明 比較例 固型パラフィン 20（％） 20（％） ワセリン 15 15 流動パラフィン 24 25 水添リン脂質 １ − DC345 40 40 上記本発明および比較例の各成分をそれぞれ透明溶液と
なるまで加温し、その後冷却した。Note 1) Dextrin fatty acid ester manufactured by Chiba Flour Milling Company Note 2) Sucrose fatty acid ester manufactured by Daiichi Pure Chemicals Company Note 3) Low molecular cyclic silicone mixture manufactured by Toray Silicone Co., Ltd. Example 2 Comparative Example of the present invention Solid paraffin 20 (%) 20 (%) Vaseline 15 15 Liquid paraffin 24 25 Hydrogenated phospholipid 1-DC345 40 40 Each of the components of the present invention and the comparative example was heated to a transparent solution, and then cooled.
実施例３ 固型パラフィン 20（％） プラスチベース 15 流動パラフィン 20 レオパールKL ５ DC345 40 実施例４ 固型パラフィン ４（％） サラシミツロウ ３ ワセリン ３ 吸着精製ラノリン 20 セタノール ３ ステアリルアルコール １ コレステロール ３ 12−ヒドロキシステアリルコレステロール ３ イソプロピルミリステート ６ オクチルドデカノール 10 レオパールKL ４ SH344 40 上記実施例１および２のゲル状組成物はなめらかな使用
感を与え、室温に60日間保存しても性状に変化は見られ
なかった。これに対して比較例１および２の基剤はボソ
ボソした使用感が残り、室温60日間の保存でその使用感
はさらに悪化した。偏光顕微鏡による観察で比較例１お
よび２の組成物では固型油脂の大きな粒子（100μｍ以
上）が観察されたのに対し、実施例１および２の組成物
では10μｍ前後の粒子が均一に分散しており、室温60日
の保存でも粒径は増大しなかった。Example 3 Solid paraffin 20 (%) Plastibase 15 Liquid paraffin 20 Leopard KL 5 DC345 40 Example 4 Solid paraffin 4 (%) Salami beeswax 3 Vaseline 3 Adsorption-purified lanolin 20 Cetanol 3 Stearyl alcohol 1 Cholesterol 3 12-Hydroxystearyl Cholesterol 3 Isopropyl myristate 6 Octyldodecanol 10 Rheopard KL 4 SH344 40 The gel compositions of Examples 1 and 2 gave a smooth feeling of use, and no change in their properties was observed even when stored at room temperature for 60 days. . On the other hand, the bases of Comparative Examples 1 and 2 still had a messy feeling of use, and the sensation of use became worse after storage at room temperature for 60 days. In the compositions of Comparative Examples 1 and 2, large particles of solid fat (100 μm or more) were observed by a polarizing microscope, whereas in the compositions of Examples 1 and 2, particles of about 10 μm were uniformly dispersed. The particle size did not increase even after storage at room temperature for 60 days.
実施例３は、汎用ゲル状組成物の例で、べとつきのな
い、サラッとした感触の軟膏基剤である。Example 3 is an example of a general-purpose gel composition, which is an ointment base having a non-greasy, dry feel.
実施例４は特にアトピー性皮膚炎や進行性指掌角皮症、
老人性痒症などの、乾燥性皮膚疾患の治療に好適なゲ
ル状の組成物で保水性の高いアルコール系の油脂分を含
有し、のびの良いサラッとした使用感を与える。Example 4 is especially atopic dermatitis and progressive keratoderma palmaris,
It is a gel-like composition suitable for treating dry skin diseases such as pruritus senilis, and contains an alcohol-based oil / fat having high water retention, and gives a smooth and smooth feeling to use.
［発明の効果］ 本発明によれば、使用に際してのべとつきがなく、さら
に長期間保存しても油脂分の晶出や結晶の増大のない皮
膚科用または化粧品用のゲル状組成物が提供される。ADVANTAGES OF THE INVENTION According to the present invention, a gel composition for dermatology or cosmetics, which is not sticky at the time of use, and is free from crystallization of fats and oils or increase in crystals even after long-term storage, is provided. It
本発明の組成物は油脂分が低分子環状シリコーンに完全
に溶解しており、低い温度でも油脂分が析出することが
ないので常になめらかでのびがよくサラッとしたさわや
かな使用感を有する。さらに本発明の組成物はゲル化剤
によってゲル化されているので油脂分の溶解状態が安定
であり、長期間の保存によっても油脂分が晶出したり、
結晶が増大したりすることがないので、なめらかな使用
感が長く維持されている。In the composition of the present invention, the oil and fat are completely dissolved in the low molecular weight cyclic silicone, and the oil and fat are not deposited even at a low temperature, so that the composition always has a smooth, smooth and refreshing feeling. Furthermore, since the composition of the present invention is gelled by a gelling agent, the dissolved state of the oil and fat is stable, and the oil and fat may crystallize even after long-term storage,
Since the crystals do not increase, a smooth feeling of use is maintained for a long time.
Claims (4)
量パーセント、以下同じ）と、低分子環状シリコーン90
〜10％とゲル化剤１〜10％とを含有してなり、前記半固
型油脂分は常温で固型である油脂５〜45％と、常温で液
状である油脂５〜45％とからなる、ゲル状組成物。1. A semi-solid oil / fat content of 10 to 90% (weight percentage in the total amount of the composition, the same applies hereinafter) and a low molecular weight cyclic silicone 90.
.About.10% and a gelling agent 1 to 10%, and the semi-solid fat and oil is composed of fat and oil 5 to 45% which is solid at room temperature and fat and oil 5 to 45% which is liquid at room temperature. Which is a gel composition.
ラシロキサンもしくはデカメチルシクロペンタシロキサ
ンまたはそれらの混合物である特許請求の範囲第１項記
載のゲル状組成物。2. The gel composition according to claim 1, wherein the cyclic silicone is octamethylcyclotetrasiloxane, decamethylcyclopentasiloxane, or a mixture thereof.
ショ糖脂肪酸エステル、セルロース誘導体およびリン脂
質の１種または２種以上よりなる特許請求の範囲第１項
記載のゲル状組成物。3. The gelling agent is a dextrin fatty acid ester,
The gel composition according to claim 1, comprising one or more of sucrose fatty acid ester, cellulose derivative and phospholipid.
求の範囲第１項記載のゲル状組成物。4. The gel composition according to claim 1, wherein the gel composition is a gel ointment base.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP62050354A JPH072631B2 (en) | 1987-03-06 | 1987-03-06 | Gel composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP62050354A JPH072631B2 (en) | 1987-03-06 | 1987-03-06 | Gel composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS63216817A JPS63216817A (en) | 1988-09-09 |
| JPH072631B2 true JPH072631B2 (en) | 1995-01-18 |
Family
ID=12856564
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP62050354A Expired - Lifetime JPH072631B2 (en) | 1987-03-06 | 1987-03-06 | Gel composition |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH072631B2 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2717593B2 (en) * | 1990-06-15 | 1998-02-18 | 千葉製粉株式会社 | Liquid oil gelling agent and method for producing the same |
| US5336692A (en) * | 1990-06-28 | 1994-08-09 | Medicis Pharmaceutical Corporation | Ointment base and method of use |
| FR2710843B1 (en) * | 1993-10-04 | 1995-12-01 | Oreal | Organopolysiloxane composition of gelled appearance, without gelling agent, usable in cosmetics and dermatology. |
| DE10024413A1 (en) * | 2000-05-19 | 2001-12-06 | Mika Pharma Gmbh | Pharmaceutical and / or cosmetic preparation |
| JP4468669B2 (en) * | 2003-09-22 | 2010-05-26 | 久光製薬株式会社 | Hypoallergenic patch |
| TWI450729B (en) * | 2008-06-12 | 2014-09-01 | Shiseido Co Ltd | Oil-in-oil type cosmetic composition |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62121764A (en) * | 1985-11-21 | 1987-06-03 | Shin Etsu Chem Co Ltd | gel composition |
| JPS62143971A (en) * | 1985-12-17 | 1987-06-27 | Shin Etsu Chem Co Ltd | gel composition |
| JPS62143970A (en) * | 1985-12-17 | 1987-06-27 | Shin Etsu Chem Co Ltd | gel composition |
| JPS63159489A (en) * | 1986-12-23 | 1988-07-02 | Shin Etsu Chem Co Ltd | gel composition |
-
1987
- 1987-03-06 JP JP62050354A patent/JPH072631B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JPS63216817A (en) | 1988-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6919970B2 (en) | Selenium disulfide composition used in the treatment of meibomian gland dysfunction | |
| TWI240635B (en) | Active vitamin D3 emulsion lotion | |
| US3906108A (en) | Stabilized tretinoin cream emulsion | |
| US4247547A (en) | Tretinoin in a gel vehicle for acne treatment | |
| JP4421801B2 (en) | Skin composition comprising coenzyme Q as an active ingredient | |
| JPWO1999044617A1 (en) | Active Vitamin D ▲Bottom 3▼ Emulsion lotion | |
| WO2008065306A1 (en) | Benzoyl peroxyde comprising compositions, at least one naphtoic acid derivative and at least one compound of polyurethane polymer-type or derivatives thereof, and their use | |
| US10314777B2 (en) | Delivery of hydrophobic bioactive agents | |
| EP1069886A1 (en) | Topical formulation of the oil-in-water type, comprising galactolipid material as emulsifier, with a prolonged effect of an incorporated active substance | |
| JP2022501314A (en) | Topical composition | |
| EP0103910A1 (en) | Emollient-containing skin conditioning compositions | |
| EP0103911A1 (en) | Emollient-containing topical pharmaceutical compositions | |
| JPH072631B2 (en) | Gel composition | |
| CN106344589B (en) | A kind of Calcipotriol betamethasone composition of improved stability | |
| US6124348A (en) | Vitamin C skin formulations | |
| CA2627021A1 (en) | Combination natural source/local anesthetic/dual component penetration enhancer topical formulation useful for treating pain, itching and/or inflammation of the skin | |
| BRPI0617045A2 (en) | composition, process for preparing a composition, use of a composition and cosmetic use of a composition | |
| JP6817733B2 (en) | Preparation for internal bleeding treatment | |
| JP7449692B2 (en) | Oil-based external composition | |
| JPS63216815A (en) | Skin protective agent | |
| JP3626482B2 (en) | Water-free skin care formulation comprising micronized urea and method for producing the same | |
| FR2901701A1 (en) | COMPOSITIONS COMPRISING AT LEAST ONE NAPHTHOIC ACID DERIVATIVE AND AT LEAST ONE FILMOGENIC AGENT, PROCESSES FOR THEIR PREPARATION, AND USES THEREOF | |
| HK40068546A (en) | Selenium disulfide compositions for use in treating meibomian gland dysfunction | |
| WO2022140467A1 (en) | Topical compositions and methods of treating skin diseases and conditions with such compositions | |
| JPH04360810A (en) | Lip cosmetic |